Biovie is trading at $1.97, up +6.12%, after positive Phase 2 SUNRISE-PD results for bezisterim.
- The results extended its sharp August 20, 2026 rally and showed statistically significant clinical and biomarker improvements versus placebo.
- The data support advancing the Parkinson’s program toward a potentially pivotal Phase 3 trial; a Schedule 13G filing also indicated fresh beneficial ownership interest.
- The broader market closed lower, making the company-specific catalyst more prominent.